Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03. Anticipation surrounds Lineage ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has dipped by 6.64%, which has investors questioning if this is right time to buy.

"A new dosing regimen to treat Bardet-Biedl Syndrome 1 (BBS1) retinal degeneration with AXV-101 (AAV9-BBS1) improves ...

Discover 6 ways to protect your eyesight naturally, from nutrition adjustments to digital habits that can significantly ...

Color vision evolved to support survival and social needs. Today, it influences how we think, feel, and navigate the world, ...

Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract ...

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data on its ...

If you've ever driven your car on a rural road at night, there's a chance that you've encountered a startled deer, but why ...

Technologies announced new preclinical data on its melanocortin agonists PL9654 and PL9655 at the 2025 Association for Research in ...

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 ...